US20070233240A1 - Intraocular lens implant - Google Patents
Intraocular lens implant Download PDFInfo
- Publication number
- US20070233240A1 US20070233240A1 US11/725,190 US72519007A US2007233240A1 US 20070233240 A1 US20070233240 A1 US 20070233240A1 US 72519007 A US72519007 A US 72519007A US 2007233240 A1 US2007233240 A1 US 2007233240A1
- Authority
- US
- United States
- Prior art keywords
- intraocular lens
- hydrogel
- set forth
- lens implant
- iol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/14—Eye parts, e.g. lenses, corneal implants; Implanting instruments specially adapted therefor; Artificial eyes
- A61F2/142—Cornea, e.g. artificial corneae, keratoprostheses or corneal implants for repair of defective corneal tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/14—Eye parts, e.g. lenses, corneal implants; Implanting instruments specially adapted therefor; Artificial eyes
- A61F2/145—Corneal inlays, onlays, or lenses for refractive correction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/26—Mixtures of macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
- A61L27/3813—Epithelial cells, e.g. keratinocytes, urothelial cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/52—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/25—Peptides having up to 20 amino acids in a defined sequence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/602—Type of release, e.g. controlled, sustained, slow
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/16—Materials or treatment for tissue regeneration for reconstruction of eye parts, e.g. intraocular lens, cornea
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/30—Synthetic polymers
Definitions
- the present invention relates generally to intraocular lens implants. More particularly, the present invention relates to intraocular lens implants that can covalently bind to a lens capsule.
- IOL intraocular lens
- IOLs are made from hard and non-swellable materials such as poly(methyl methacrylate) (PMMA) and silicone, which do not accommodate when placed in the eye. They are typically secured within the lens capsule through two polymeric haptics, which extend radially from the device.
- PMMA poly(methyl methacrylate)
- silicone silicone
- the most recent innovation involves “foldable” IOLs that permit smaller incisions during their implantation. Some are able to facilitate accommodation, but not by the eye's natural mechanism. Another concern with current IOLs is their inability to prevent secondary opacification of the posterior capsule, thus requiring laser treatment. Accordingly, there is a need in the art to develop an IOL implant that can be implanted with a small incision, can prevent secondary opacification of the posterior capsule, and that can accommodate by the eye's natural mechanism.
- the present invention provides a hydrogel-based intraocular lens (IOL) implant that can covalently attach to a lens capsule on implantation into an eye.
- the covalent binding of the IOL to the lens capsule is preferably mediated by active functional groups covalently linked to a surface of a hydrogel, for example through a photoreactive azide.
- the active functional groups are preferably N-hydroxysuccinimide functional groups tethered to the surface of the hydrogel. This tethering may be accomplished by use of a bifunctional chemical linker such as 5-azido-2-nitrobenzoic acid N-hydroxysuccinimide ester. Exposure to UV light converts the azide group of this linker to reactive nitrene groups that bind to the surface of hydrogels.
- N-hydroxysuccinimide (NHS) groups free to form peptide linkages with proteins in the lens capsule via free amines on the lens capsule proteins.
- the NHS groups may bind to collagen, such as collagen type I and collagen type III, which is naturally present in the lens capsule.
- the adhesion of the hydrogel to proteins by this esterification process occurs rapidly in aqueous solution at pH 7.4 if the materials are brought into close, sustained contact.
- the IOL has a high refractive index, high elasticity, and is of a similar size to a naturally occurring lens.
- the IOL can be implanted in a smaller, dehydrated state, allowing the IOL to be placed in the lens capsule with a small incision (up to about 1/10 the volume of the IOL). Exposure to fluid can then initiate rapid swelling of the dried polymer to the shape and dimensions of a natural lens, with full occupation of the lens capsule. Upon equilibrium swelling, the IOL can then make contact with the inner aspect of the lens capsule and covalently bind to it via the active-ester surface functionalization of the hydrogel. By this attachment process, the IOL will be in a position to accommodate in a manner identical to that of the natural lens.
- FIG. 1 shows a schematic of swelling of an IOL according to the present invention on implantation into a lens capsule.
- FIG. 2 shows time-dependence of the water content of a single network PEG hydrogels and PEG/PAA IPNs with different amounts of acrylic acid (AA).
- FIG. 3 shows appearance of a PEG/PAA IPN based on PEG MW 4600 in the dried state (a) and after being immersed for 40 minutes in PBS, pH 7.4.
- FIG. 4 shows a schematic of covalent binding of an IOL according to the present invention to a lens capsule.
- FIG. 5 shows binding of collagen-fluorescein isothiocyanate (FITC) to an IOL according to the present invention.
- the present invention provides a hydrogel-based IOL capable of covalently binding to a lens capsule upon implantation into an eye.
- the hydrogel may be composed of any polymer capable of rapid swelling upon hydration.
- FIG. 1A shows a dehydrated IOL 110 that has been implanted through incision 120 in cornea 122 into lens capsule 130 .
- FIG. 1B dehydrated IOL becomes partially hydrated 112 on exposure to the aqueous environment of the lens capsule 130 .
- FIG. 1C the IOL is fully swollen 114 within lens capsule 130 . Fully swollen IOL 114 can then be controlled by zonules 140 to accommodate the curvature of the lens to different distances.
- the hydrogel can swell from a dehydrated state to a rehydrated state within about 2 hours.
- the volume and weight ratios of dehydrated versus rehydrated hydrogel are between about 10:90 (dry:swollen) and about 40:60 (dry:swollen).
- the water content of a dehydrated hydrogel is preferably between about 0 and about 30%, whereas the rehydrated water content of the hydrogel is preferably between about 60 and about 90%.
- FIG. 3 shows that PEG/PAA IPNs also swell rapidly under physiological conditions.
- FIG. 3A shows the hydrogel in a dehydrated state.
- FIG. 3B shows the hydrogel 40 minutes after hydration with PBS pH 7.4. A penny is shown in both parts of the figure for comparison of size).
- the IOLs are preferably made of homopolymer, copolymer, or interpenetrating networks based on poly(ethylene glycol) (PEG) and/or poly(acrylic acid) (PAA). Due to their high degree of hydrophilicity, polymer networks of PEG and PAA rapidly swell upon exposure to water. Moreover, at physiologic pH (7.4 to 7.6), the carboxylic acid groups on PAA (pKa 4.7) ionize, causing the polymer chains to repel each other and the network to take up even more water. Both PEG and PAA are biocompatible.
- polymer components suitable for practicing the invention include PEG and PAA derivatives as well as poly(vinyl alcohol), poly(2-hydroxy ethylacrylate), poly(2-hydroxyethyl methacrylate), poly(methacrylic acid) and their derivatives.
- the hydrogels can be polymerized in elliptical molds or reshaped after polymerization by lathing or by use of lasers such as a femtosecond laser.
- a typical hydrated lens is about 9.5 mm wide and 4.0-4.5 mm thick.
- Partially dehydrated lenses can be around 7.0 mm wide and 2.0 mm thick, and fully dehydrated lenses can be as small as 2.0 mm wide and less than 1.0 mm thick.
- hydrogels based on PEG and PAA have a low elastic modulus at physiologic pH, which allows IOLs made from these materials to accommodate by ciliary muscle-mediated circumferential tension on the lens capsule.
- High MW PEG macromers ⁇ 8000
- the preferred elastic modulus values are on the order of between about 1 kPa and about 250 kPa. Table 1 shows hydrogels of varying polymer composition and formulation.
- hydrogels of various rehydrated water content (84%-96%), tensile strength ( ⁇ max ) and elastic modulus (E 0 ) values (50 kPa-250 kPa) can be synthesized.
- the water content of a given hydrogel can be raised or lowered by changing the molecular weight or relative composition of the components of a hydrogel, or by simply changing the amount of polymer precursor (monomer) at the time of polymerization.
- the elastic modulus of the human lens is roughly 1 kPa.
- the hydrogels are engineered to match the refractive index of the human lens (1.42) by modulation of the relative content of PEG (1.46), PAA (1.52) and water (1.33).
- the refractive index of the hydrogel can be modulated in either of two ways: (1) by increasing the relative polymer content and/or (2) by the addition of high refractive index additives as either a filler material or as a co-polymeric element.
- the refractive index of the material will be higher due to a greater proportion of materials (relative to water) with high refractive index.
- the range of preferred refractive index values are from about 1.33 to about 1.42.
- the swollen weight ratios of water to polymer in these combinations can range from about 1:1 to about 1:10.
- an azide-active-ester chemical containing a photoreactive azide on one end and an N-hydroxysuccinimide (NHS) group (which can covalently bind to cell adhesion proteins and peptides) on the other end can be used.
- An example of such a linker is 5-azido-2-nitrobenzoic acid N-hydroxysuccinimide ester.
- Another example of a bifunctional linker is 6-(4-azido-2-nitrophenylamino)hexanoic acid N-hydroxysuccinimide ester, which has a longer spacer arm between the reactive end groups.
- novel spacer arms that are both longer and more hydrophilic can be synthesized by conjugating 5-azido-2-nitrobenzoic acid N-hydroxysuccinimide ester with amine-terminated PEG macromers, which can then be further functionalized to possess NHS moieties that can bind to protein/peptides.
- 5-azido-2-nitrobenzoic acid N-hydroxysuccinimide ester is dissolved in 1 mL of N,N-dimethylformamide (DMF) (See Matsuda et al. (1990) in a paper entitled “ Development of micropatterning technology for cultured cells ” and published in “ ASAIO Transactions 36(3):M559-562”).
- DMF N,N-dimethylformamide
- swollen IOL 410 which has been functionalized with 5-azido-2-nitrobenzoyloxy-N-hydroxysuccinimide, makes sustained contact with lens capsule 420 .
- the functionalized IOL covalently binds to the lens capsule through free amines on proteins present in the lens capsule.
- Hydrogels that have been functionalized with 5-azido-2-nitrobenzoyloxy-N-hydroxysuccinimide can bind collagen, a protein normally found in the lens capsule, as shown in FIG. 5 .
- an IOL according to the present invention was incubated in a 0.1% collagen-FITC solution for 24 hours at 37 degrees C.
- FIG. 5A shows binding of collagen-FITC to the surface of the IOL.
- collagen type I was used.
- IOLs according to the present invention may be used for any condition whereby the natural lens is damaged, missing, or defective. Examples include lens replacement for people suffering from cataracts and for people with age-related hardening of the lens (presbyopia).
- IOLs according to the present invention preferably prevent secondary opacification of the posterior capsule. It does so by eliminating the potential space between the lens capsule and the lens element in which opacification typically occurs in vivo.
Abstract
The present invention provides a hydrogel-based intraocular lens (IOL) implant that can covalently attach to a lens capsule on implantation into an eye. The inventive IOL has a high refractive index, high elasticity, and is of a similar size to a naturally occurring lens. In addition, the IOL can be implanted in a smaller, dehydrated state, allowing the IOL to be placed in the lens capsule with a small incision (up to about 1/10 the volume of the IOL). Exposure to fluid can then initiate rapid swelling of the dried polymer to the shape and dimensions of a natural lens, with full occupation of the lens capsule. Upon equilibrium swelling, the IOL can then make contact with the inner aspect of the lens capsule and covalently bind to it. By this attachment process, the IOL may accommodate in a manner identical to that of the natural lens.
Description
- This application claims priority from U.S. Provisional Patent Application No. 60/783,601, filed Mar. 17, 2006, which is incorporated herein by reference.
- This application is a continuation-in-part of U.S. patent application Ser. No. 11/243,952, filed Oct. 4, 2005, which claims priority from U.S. Provisional Patent Application No. 60/616,262, filed Oct. 5, 2004, and from U.S. Provisional Patent Application No. 60/673,172, filed Apr. 20, 2005, all of which are incorporated by reference herein.
- This application is also a continuation-in-part of U.S. application Ser. No. 11/409,218, filed Apr. 20, 2006, which claims priority from U.S. Provisional Patent Application No. 60/673,600, filed Apr. 21, 2005, and which is a continuation-in-part of U.S. patent application Ser. No. 11/243,952, filed Oct. 4, 2005, all of which are incorporated by reference herein.
- This application is also a continuation-in-part of U.S. patent application Ser. No. 11/636,114, filed Dec. 7, 2006, which claims priority from U.S. Provisional Application Nos. 60/843,942, filed on Sep. 11, 2006, and 60/783,307, filed Mar. 17, 2006, both of which are incorporated herein by reference. U.S. patent application Ser. No. 11/636,114 is a continuation-in part of U.S. patent application Ser. No. 11/243,952, filed Oct. 4, 2005, and of U.S. application Ser. No. 11/409,218, filed Apr. 20, 2006, both of which are incorporated by reference herein.
- This application is also a continuation-in-part of U.S. application Ser. No. 11/639,049, filed Dec. 13, 2006, which claims priority from U.S. Provisional Patent Application No. 60/843,942, filed Sep. 11, 2006, both of which are incorporated herein by reference. U.S. application Ser. No. 11/639,049 is a continuation-in part of U.S. patent application Ser. No. 11/243,952, filed Oct. 4, 2005 and of U.S. application Ser. No. 11/409,218, filed Apr. 20, 2006
- The present invention relates generally to intraocular lens implants. More particularly, the present invention relates to intraocular lens implants that can covalently bind to a lens capsule.
- Cataract extraction is among the most commonly performed operations in the United States and the world. There are an estimated 20 million people worldwide who suffer from cataracts. In the United States alone, 1.5 million people have cataract surgery each year. Following removal of a cataractous lens, an intraocular lens (IOL) implant is typically implanted within the lens capsule in order to mimic the refractive function of healthy natural lens.
- Current IOLs are made from hard and non-swellable materials such as poly(methyl methacrylate) (PMMA) and silicone, which do not accommodate when placed in the eye. They are typically secured within the lens capsule through two polymeric haptics, which extend radially from the device. The most recent innovation involves “foldable” IOLs that permit smaller incisions during their implantation. Some are able to facilitate accommodation, but not by the eye's natural mechanism. Another concern with current IOLs is their inability to prevent secondary opacification of the posterior capsule, thus requiring laser treatment. Accordingly, there is a need in the art to develop an IOL implant that can be implanted with a small incision, can prevent secondary opacification of the posterior capsule, and that can accommodate by the eye's natural mechanism.
- The present invention provides a hydrogel-based intraocular lens (IOL) implant that can covalently attach to a lens capsule on implantation into an eye. The covalent binding of the IOL to the lens capsule is preferably mediated by active functional groups covalently linked to a surface of a hydrogel, for example through a photoreactive azide. The active functional groups are preferably N-hydroxysuccinimide functional groups tethered to the surface of the hydrogel. This tethering may be accomplished by use of a bifunctional chemical linker such as 5-azido-2-nitrobenzoic acid N-hydroxysuccinimide ester. Exposure to UV light converts the azide group of this linker to reactive nitrene groups that bind to the surface of hydrogels. This leaves the N-hydroxysuccinimide (NHS) groups free to form peptide linkages with proteins in the lens capsule via free amines on the lens capsule proteins. For example, the NHS groups may bind to collagen, such as collagen type I and collagen type III, which is naturally present in the lens capsule. The adhesion of the hydrogel to proteins by this esterification process occurs rapidly in aqueous solution at pH 7.4 if the materials are brought into close, sustained contact.
- Preferably, the IOL has a high refractive index, high elasticity, and is of a similar size to a naturally occurring lens. Also preferably, the IOL can be implanted in a smaller, dehydrated state, allowing the IOL to be placed in the lens capsule with a small incision (up to about 1/10 the volume of the IOL). Exposure to fluid can then initiate rapid swelling of the dried polymer to the shape and dimensions of a natural lens, with full occupation of the lens capsule. Upon equilibrium swelling, the IOL can then make contact with the inner aspect of the lens capsule and covalently bind to it via the active-ester surface functionalization of the hydrogel. By this attachment process, the IOL will be in a position to accommodate in a manner identical to that of the natural lens.
- The present invention together with its objectives and advantages will be understood by reading the following description in conjunction with the drawings, in which:
-
FIG. 1 shows a schematic of swelling of an IOL according to the present invention on implantation into a lens capsule. -
FIG. 2 shows time-dependence of the water content of a single network PEG hydrogels and PEG/PAA IPNs with different amounts of acrylic acid (AA). The hydrogels were placed in deionized water in the dry state at time=0 and then weighed at regular intervals. -
FIG. 3 shows appearance of a PEG/PAA IPN based on PEG MW 4600 in the dried state (a) and after being immersed for 40 minutes in PBS, pH 7.4. -
FIG. 4 shows a schematic of covalent binding of an IOL according to the present invention to a lens capsule. -
FIG. 5 shows binding of collagen-fluorescein isothiocyanate (FITC) to an IOL according to the present invention. - The present invention provides a hydrogel-based IOL capable of covalently binding to a lens capsule upon implantation into an eye. The hydrogel may be composed of any polymer capable of rapid swelling upon hydration. A schematic of swelling of an IOL on implantation into a lens capsule is shown in
FIG. 1 .FIG. 1A shows a dehydrated IOL 110 that has been implanted throughincision 120 incornea 122 intolens capsule 130. InFIG. 1B , dehydrated IOL becomes partially hydrated 112 on exposure to the aqueous environment of thelens capsule 130. InFIG. 1C , the IOL is fully swollen 114 withinlens capsule 130. Fullyswollen IOL 114 can then be controlled byzonules 140 to accommodate the curvature of the lens to different distances. - Preferably, the hydrogel can swell from a dehydrated state to a rehydrated state within about 2 hours. Also preferably, the volume and weight ratios of dehydrated versus rehydrated hydrogel are between about 10:90 (dry:swollen) and about 40:60 (dry:swollen). The water content of a dehydrated hydrogel is preferably between about 0 and about 30%, whereas the rehydrated water content of the hydrogel is preferably between about 60 and about 90%.
FIG. 2 shows time-dependence of the water content of a single network PEG hydrogels and PEG/PAA IPNs with different amounts of acrylic acid (AA). The hydrogels were placed in deionized water in the dry state at time=0 and then weighed at regular intervals. This graphs shows that both single network PEG hydrogels and PEG/PAA IPNs swell rapidly in deionized water.FIG. 3 shows that PEG/PAA IPNs also swell rapidly under physiological conditions. (FIG. 3A shows the hydrogel in a dehydrated state.FIG. 3B shows thehydrogel 40 minutes after hydration with PBS pH 7.4. A penny is shown in both parts of the figure for comparison of size). - The IOLs are preferably made of homopolymer, copolymer, or interpenetrating networks based on poly(ethylene glycol) (PEG) and/or poly(acrylic acid) (PAA). Due to their high degree of hydrophilicity, polymer networks of PEG and PAA rapidly swell upon exposure to water. Moreover, at physiologic pH (7.4 to 7.6), the carboxylic acid groups on PAA (pKa 4.7) ionize, causing the polymer chains to repel each other and the network to take up even more water. Both PEG and PAA are biocompatible. Other polymer components suitable for practicing the invention include PEG and PAA derivatives as well as poly(vinyl alcohol), poly(2-hydroxy ethylacrylate), poly(2-hydroxyethyl methacrylate), poly(methacrylic acid) and their derivatives.
- The hydrogels can be polymerized in elliptical molds or reshaped after polymerization by lathing or by use of lasers such as a femtosecond laser. A typical hydrated lens is about 9.5 mm wide and 4.0-4.5 mm thick. Partially dehydrated lenses can be around 7.0 mm wide and 2.0 mm thick, and fully dehydrated lenses can be as small as 2.0 mm wide and less than 1.0 mm thick.
- When PAA is polymerized in the presence of an existing PEG-diacrylate hydrogel network, an interpenetrating polymer network (IPN) structure is formed. These materials exhibit reversible, reproducible, swelling behavior with dehydration and hydration in aqueous solution. Details on PAA/PEG IPNs can be found in U.S. patent application Ser. No. 11/243952, which is incorporated by reference herein.
- Like a human lens, hydrogels based on PEG and PAA have a low elastic modulus at physiologic pH, which allows IOLs made from these materials to accommodate by ciliary muscle-mediated circumferential tension on the lens capsule. High MW PEG macromers (≧8000) have low elastic moduli and are suitable for use in these devices. In addition, PAA polymers with low crosslinking density (≦mol 1%) and high water content (≧80%) have low elastic moduli. The preferred elastic modulus values are on the order of between about 1 kPa and about 250 kPa. Table 1 shows hydrogels of varying polymer composition and formulation. Depending on the type of polymer (PEG or PAA), its molecular weight (8000 kDa or 14000 kDa), or whether it is a homopolymer, copolymer, or an interpenetrating network, hydrogels of various rehydrated water content (84%-96%), tensile strength (σmax) and elastic modulus (E0) values (50 kPa-250 kPa) can be synthesized. The water content of a given hydrogel can be raised or lowered by changing the molecular weight or relative composition of the components of a hydrogel, or by simply changing the amount of polymer precursor (monomer) at the time of polymerization. The elastic modulus of the human lens is roughly 1 kPa.
TABLE 1 Properties of PEG and PAA-based hydrogels specimen WC (%) σmax (MPa) Eo (MPa) PAA 95.5 ± 1.7 0.068 ± 0.015 0.050 ± 0.001 PEG(8.0k) 90.5 ± 1.2 0.273 ± 0.036 0.199 ± 0.075 PEG(14.0k) 95.1 ± 1.2 0.073 ± 0.070 0.062 ± 0.005 PEG(14.0k)/PAA* 84.3 ± 1.7 0.247 ± 0.046 0.177 ± 0.013 PEG(8.0k)-co-PAA** 90.54 ± 0.08 0.275 ± 0.025 0.250 ± 0.013
*interpenetrating network
**copolymer network
- Preferably, the hydrogels are engineered to match the refractive index of the human lens (1.42) by modulation of the relative content of PEG (1.46), PAA (1.52) and water (1.33). The refractive index of the hydrogel can be modulated in either of two ways: (1) by increasing the relative polymer content and/or (2) by the addition of high refractive index additives as either a filler material or as a co-polymeric element. By increasing the content of PEG and PAA relative to water, the refractive index of the material will be higher due to a greater proportion of materials (relative to water) with high refractive index. The range of preferred refractive index values are from about 1.33 to about 1.42. The swollen weight ratios of water to polymer in these combinations can range from about 1:1 to about 1:10.
- To mediate covalent binding of the IOL to the lens capsule, an azide-active-ester chemical containing a photoreactive azide on one end and an N-hydroxysuccinimide (NHS) group (which can covalently bind to cell adhesion proteins and peptides) on the other end can be used. An example of such a linker is 5-azido-2-nitrobenzoic acid N-hydroxysuccinimide ester. Another example of a bifunctional linker is 6-(4-azido-2-nitrophenylamino)hexanoic acid N-hydroxysuccinimide ester, which has a longer spacer arm between the reactive end groups. In addition, novel spacer arms that are both longer and more hydrophilic can be synthesized by conjugating 5-azido-2-nitrobenzoic acid N-hydroxysuccinimide ester with amine-terminated PEG macromers, which can then be further functionalized to possess NHS moieties that can bind to protein/peptides. In one example, 5 mg of 5-azido-2-nitrobenzoic acid N-hydroxysuccinimide ester is dissolved in 1 mL of N,N-dimethylformamide (DMF) (See Matsuda et al. (1990) in a paper entitled “Development of micropatterning technology for cultured cells” and published in “ASAIO Transactions 36(3):M559-562”). This solution is then evenly spread over the hydrogel surface and exposed to UV for 5 minutes after the hydrogel surface is air-dried. Upon UV irradiation, the phenyl azide group reacts to form covalent bonds with the hydrogel surface. The irradiated surfaces are then thoroughly rinsed with solvent to remove any unreacted chemicals from the surface. This results in hydrogels with exposed NHS end groups on the surface. These exposed NHS end groups can then covalently bind to a lens capsule upon implantation of the IOL into the lens capsule, as shown in
FIG. 4 . - In
FIG. 4 ,swollen IOL 410, which has been functionalized with 5-azido-2-nitrobenzoyloxy-N-hydroxysuccinimide, makes sustained contact withlens capsule 420. This in turn allows the functionalized IOL to covalently bind 430 to thelens capsule 420. Preferably, the functionalized IOL covalently binds to the lens capsule through free amines on proteins present in the lens capsule. - Hydrogels that have been functionalized with 5-azido-2-nitrobenzoyloxy-N-hydroxysuccinimide can bind collagen, a protein normally found in the lens capsule, as shown in
FIG. 5 . InFIG. 5A , an IOL according to the present invention was incubated in a 0.1% collagen-FITC solution for 24 hours at 37 degrees C. In contrast toFIG. 5B , which was not reacted with collagen-FITC,FIG. 5A shows binding of collagen-FITC to the surface of the IOL. In this experiment, collagen type I was used. - IOLs according to the present invention may be used for any condition whereby the natural lens is damaged, missing, or defective. Examples include lens replacement for people suffering from cataracts and for people with age-related hardening of the lens (presbyopia).
- In addition, IOLs according to the present invention preferably prevent secondary opacification of the posterior capsule. It does so by eliminating the potential space between the lens capsule and the lens element in which opacification typically occurs in vivo.
- As one of ordinary skill in the art will appreciate, various changes, substitutions, and alterations could be made or otherwise implemented without departing from the principles of the present invention. Accordingly, the scope of the invention should be determined by the following claims and their legal equivalents.
Claims (14)
1. An intraocular lens implant, comprising:
(a) a hydrogel; and
(b) active functional groups covalently linked to a surface of said hydrogel,
wherein said active functional groups mediate covalent binding of said intraocular lens implant to an eye's lens capsule upon implantation of said intraocular lens implant into said lens capsule.
2. The intraocular lens implant as set forth in claim 1 , wherein said active functional groups comprise N-hydroxysuccinimide.
3. The intraocular lens implant as set forth in claim 1 , wherein said active functional groups are covalently linked to said surface of said hydrogel through a photoreactive azide.
4. The intraocular lens implant as set forth in claim 3 , wherein said photoreactive azide comprises 5-Azido-2-nitrobenzoic acid N-hydroxysuccinimide ester.
5. The intraocular lens implant as set forth in claim 1 , wherein said active functional groups covalently bind to proteins in said lens capsule.
6. The intraocular lens implant as set forth in claim 5 , wherein said proteins are at least one of collagen, collagen type I and collagen type III
7. The intraocular lens implant as set forth in claim 1 , wherein said active functional groups covalently bind to said lens capsule via free amines on proteins present in said lens capsule.
8. The intraocular lens implant as set forth in claim 1 , wherein said hydrogel can swell from a dehydrated state to a rehydrated state within about 2 hours.
9. The intraocular lens implant as set forth in claim 1 , wherein the weight and volume ratios of said hydrogel in a dehydrated versus a hydrated state are between about 10:90 and about 40:60.
10. The intraocular lens implant as set forth in claim 1 , wherein water content of said hydrogel in a dehydrated state is between about 0 and about 30%.
11. The intraocular lens implant as set forth in claim 1 , wherein water content of said hydrogel in a rehydrated state is between about 60 and about 90%.
12. The intraocular lens implant as set forth in claim 1 , wherein said hydrogel is a homopolymer, copolymer or interpenetrating network based on at least one of poly(ethylene glycol), poly(acrylic acid), poly(vinyl alcohol), poly(2-hydroxy ethylacrylate), poly(2-hydroxyethyl methacrylate), poly(methacrylic acid) and their derivatives.
13. The intraocular lens implant as set forth in claim 1 , wherein said hydrogel has an elastic modulus of between about 1 kPa and about 250 kPa.
14. The intraocular lens implant as set forth in claim 1 , wherein said hydrogel has a refractive index of between about 1.33 to about 1.42.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/725,190 US20070233240A1 (en) | 2004-10-05 | 2007-03-16 | Intraocular lens implant |
Applications Claiming Priority (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61626204P | 2004-10-05 | 2004-10-05 | |
US67317205P | 2005-04-20 | 2005-04-20 | |
US67360005P | 2005-04-21 | 2005-04-21 | |
US11/243,952 US7857849B2 (en) | 2004-10-05 | 2005-10-04 | Artificial corneal implant |
US78330706P | 2006-03-17 | 2006-03-17 | |
US78360106P | 2006-03-17 | 2006-03-17 | |
US11/409,218 US20060287721A1 (en) | 2004-10-05 | 2006-04-20 | Artificial cornea |
US84394206P | 2006-09-11 | 2006-09-11 | |
US11/636,114 US7857447B2 (en) | 2004-10-05 | 2006-12-07 | Interpenetrating polymer network hydrogel contact lenses |
US11/639,049 US7909867B2 (en) | 2004-10-05 | 2006-12-13 | Interpenetrating polymer network hydrogel corneal prosthesis |
US11/725,190 US20070233240A1 (en) | 2004-10-05 | 2007-03-16 | Intraocular lens implant |
Related Parent Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/243,952 Continuation-In-Part US7857849B2 (en) | 2004-10-05 | 2005-10-04 | Artificial corneal implant |
US11/409,218 Continuation-In-Part US20060287721A1 (en) | 2004-10-05 | 2006-04-20 | Artificial cornea |
US11/636,114 Continuation-In-Part US7857447B2 (en) | 2004-10-05 | 2006-12-07 | Interpenetrating polymer network hydrogel contact lenses |
US11/639,049 Continuation-In-Part US7909867B2 (en) | 2004-10-05 | 2006-12-13 | Interpenetrating polymer network hydrogel corneal prosthesis |
Publications (1)
Publication Number | Publication Date |
---|---|
US20070233240A1 true US20070233240A1 (en) | 2007-10-04 |
Family
ID=36149013
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/243,952 Expired - Fee Related US7857849B2 (en) | 2004-10-05 | 2005-10-04 | Artificial corneal implant |
US11/725,190 Abandoned US20070233240A1 (en) | 2004-10-05 | 2007-03-16 | Intraocular lens implant |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/243,952 Expired - Fee Related US7857849B2 (en) | 2004-10-05 | 2005-10-04 | Artificial corneal implant |
Country Status (3)
Country | Link |
---|---|
US (2) | US7857849B2 (en) |
EP (1) | EP1809207A4 (en) |
WO (1) | WO2006042272A2 (en) |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090017097A1 (en) * | 2007-07-09 | 2009-01-15 | Sawhney Amarpreet S | Hydrogel polymeric compositions and methods |
US20110166247A1 (en) * | 2006-12-07 | 2011-07-07 | David Myung | Interpenetrating polymer network hydrogel contact lenses |
US20120071580A1 (en) * | 2008-07-31 | 2012-03-22 | The Board Of Trustees Of The University Of Illinois | Suturable Hybrid Superporous Hydrogel Keratoprosthesis for Cornea |
US8409606B2 (en) | 2009-02-12 | 2013-04-02 | Incept, Llc | Drug delivery through hydrogel plugs |
WO2013106618A1 (en) * | 2012-01-11 | 2013-07-18 | Advanced Vision Science, Inc. | Polarized component ocular devices |
US8497023B2 (en) | 2008-08-05 | 2013-07-30 | Biomimedica, Inc. | Polyurethane-grafted hydrogels |
US20130231740A1 (en) * | 2012-03-05 | 2013-09-05 | Key Medical Technologies, Inc. | Polymers and methods for ophthalmic applications |
US8679190B2 (en) | 2004-10-05 | 2014-03-25 | The Board Of Trustees Of The Leland Stanford Junior University | Hydrogel arthroplasty device |
US8883915B2 (en) | 2008-07-07 | 2014-11-11 | Biomimedica, Inc. | Hydrophobic and hydrophilic interpenetrating polymer networks derived from hydrophobic polymers and methods of preparing the same |
US8961501B2 (en) | 2010-09-17 | 2015-02-24 | Incept, Llc | Method for applying flowable hydrogels to a cornea |
US9114024B2 (en) | 2011-11-21 | 2015-08-25 | Biomimedica, Inc. | Systems, devices, and methods for anchoring orthopaedic implants to bone |
WO2017059272A1 (en) * | 2015-09-30 | 2017-04-06 | Microoptx Inc. | Dry eye treatment devices and methods |
US10039859B2 (en) | 2013-09-09 | 2018-08-07 | Uab Ferentis | Transparent hydrogel and method of making the same from functionalized natural polymers |
US10166314B2 (en) | 2013-10-14 | 2019-01-01 | Uab Ferentis | Regenerative prostheses as alternatives to donor corneas for transplantation |
US10226417B2 (en) | 2011-09-16 | 2019-03-12 | Peter Jarrett | Drug delivery systems and applications |
US10457803B2 (en) | 2008-07-07 | 2019-10-29 | Hyalex Orthopaedics, Inc. | Orthopedic implants having gradient polymer alloys |
US10736778B2 (en) | 2014-12-31 | 2020-08-11 | Microoptx Inc. | Glaucoma treatment devices and methods |
US10792392B2 (en) | 2018-07-17 | 2020-10-06 | Hyalex Orthopedics, Inc. | Ionic polymer compositions |
US11015016B2 (en) | 2011-10-03 | 2021-05-25 | Hyalex Orthopaedics, Inc. | Polymeric adhesive for anchoring compliant materials to another surface |
US11077228B2 (en) | 2015-08-10 | 2021-08-03 | Hyalex Orthopaedics, Inc. | Interpenetrating polymer networks |
US11369591B2 (en) | 2015-05-12 | 2022-06-28 | Incept, Llc | Drug delivery from hydrogels |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1549255A4 (en) * | 2002-09-13 | 2007-12-19 | Coopervision Inc | Devices and methods for improving vision |
CA2577025C (en) * | 2004-08-13 | 2014-01-28 | Ottawa Health Research Institute | Vision enhancing ophthalmic devices and related methods and compositions |
US20060074182A1 (en) * | 2004-09-30 | 2006-04-06 | Depuy Products, Inc. | Hydrogel composition and methods for making the same |
US8821583B2 (en) * | 2004-10-05 | 2014-09-02 | The Board Of Trustees Of The Leland Stanford Junior University | Interpenetrating polymer network hydrogel |
US20060287721A1 (en) * | 2004-10-05 | 2006-12-21 | David Myung | Artificial cornea |
US9999497B2 (en) * | 2005-01-31 | 2018-06-19 | Yichieh Shiuey | Corneal implants and methods and systems for placement |
CN101305052B (en) * | 2005-09-09 | 2012-10-10 | 渥太华健康研究所 | Interpenetrating networks, and related methods and compositions |
US8945197B1 (en) | 2005-10-24 | 2015-02-03 | Lockheed Martin Corporation | Sight-restoring visual prosthetic and method using infrared nerve-stimulation light |
US8709078B1 (en) | 2011-08-03 | 2014-04-29 | Lockheed Martin Corporation | Ocular implant with substantially constant retinal spacing for transmission of nerve-stimulation light |
US8956396B1 (en) | 2005-10-24 | 2015-02-17 | Lockheed Martin Corporation | Eye-tracking visual prosthetic and method |
WO2008097616A1 (en) * | 2007-02-06 | 2008-08-14 | The Board Of Trustees Of The Leland Stanford Junior University | Hydrogel-metal assembly |
WO2008100617A1 (en) * | 2007-02-16 | 2008-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | Strain-hardened interpenetrating polymer network hydrogel |
WO2008130604A2 (en) * | 2007-04-17 | 2008-10-30 | The Board Of Trustees Of The Leland Stanford Junior University | Hydrogel arthroplasty device |
WO2008131410A1 (en) * | 2007-04-23 | 2008-10-30 | The General Hospital Corporation Dba | Pva hydrogels having improved creep resistance, lubricity, and toughness |
US20090117166A1 (en) * | 2007-08-15 | 2009-05-07 | David Myung | Sequential coupling of biomolecule layers to polymers |
EP2193018A4 (en) * | 2007-09-05 | 2011-01-26 | Gen Hospital Corp | Creep resistant, highly lubricious, tough, and ionic hydrogels including pva-paamps hydrogels |
US20100280147A1 (en) * | 2008-02-15 | 2010-11-04 | Laura Hartmann | High refractive index interpenetrating networks for ophthalmic applications |
US20090220578A1 (en) * | 2008-02-28 | 2009-09-03 | Depuy Products, Inc. | Hydrogel composition and method for making the same |
US20090240337A1 (en) * | 2008-03-21 | 2009-09-24 | David Myung | Methods, Devices and Compositions for Adhering Hydrated Polymer Implants to Bone |
US9125735B2 (en) * | 2008-04-04 | 2015-09-08 | Forsight Labs, Llc | Method of correcting vision using corneal onlays |
EP2296580A2 (en) * | 2008-04-04 | 2011-03-23 | Forsight Labs, Llc | Corneal onlay devices and methods |
CA2720250C (en) | 2008-04-04 | 2018-01-23 | Forsight Labs, Llc | Therapeutic device for pain management and vision |
WO2009134414A2 (en) * | 2008-04-30 | 2009-11-05 | The Board Of Trustees Of The Leland Stanford Junior University | Devices for the treatment of wounds and methods and kits thereof |
WO2009144569A2 (en) * | 2008-05-29 | 2009-12-03 | Politecnico Di Milano | Hydrogel capable of containing and conveying cells |
ITMI20082037A1 (en) * | 2008-11-17 | 2010-05-18 | Milano Politecnico | HYDROGEL SUITABLE FOR CONTAINING AND CARRYING CELLS |
WO2010005992A1 (en) * | 2008-07-07 | 2010-01-14 | Biomimedica, Inc. | Hydrophilic interpenetrating polymer networks derived from hydrophobic polymers |
US20100080840A1 (en) * | 2008-07-31 | 2010-04-01 | Michael Cho | Hybrid superporous hydrogel scaffold for cornea regeneration |
WO2011038485A1 (en) * | 2009-09-30 | 2011-04-07 | Ottawa Hospital Research Institute | Crosslinked hydrogels and related method of preparation |
US8591025B1 (en) | 2012-09-11 | 2013-11-26 | Nexisvision, Inc. | Eye covering and refractive correction methods for LASIK and other applications |
EP2490620A4 (en) | 2009-10-23 | 2017-03-22 | Forsight Labs, Llc | Conformable therapeutic shield for vision and pain |
ES2649890T3 (en) | 2009-10-23 | 2018-01-16 | Nexisvision, Inc. | Corneal enervation for the treatment of eye pain |
FR2952298B1 (en) * | 2009-11-06 | 2012-05-25 | Gilbert Cohen | INTRACORNEAN DIFFRACTIVE LENS WITH PHASE INVERSION |
FR2952297B1 (en) * | 2009-11-06 | 2012-03-30 | Gilbert Cohen | INTRACORNEAN DIFFRACTIVE LENS |
US20110152868A1 (en) * | 2009-12-18 | 2011-06-23 | Lampros Kourtis | Method, device, and system for shaving and shaping of a joint |
WO2011097619A2 (en) * | 2010-02-08 | 2011-08-11 | Regents Of The University Of Minnesota | Silica-based composite ocular device and methods |
ES2704162T3 (en) | 2010-09-30 | 2019-03-14 | Keramed Inc | Reversible deformable artificial cornea |
CN103281995B (en) | 2010-10-25 | 2016-04-06 | 内希斯视觉股份有限公司 | Identify the method and apparatus for the eyes covering of vision |
US9211256B2 (en) | 2011-03-08 | 2015-12-15 | The Johns Hopkins University | Wound healing compositions comprising biocompatible cellulose hydrogel membranes and methods of use thereof |
US9175153B2 (en) | 2011-03-08 | 2015-11-03 | The Johns Hopkins University | Cellulose hydrogel compositions and contact lenses for corneal applications |
US8871016B2 (en) | 2011-08-03 | 2014-10-28 | The Johns Hopkins University | Cellulose-based hydrogels and methods of making thereof |
EP2688397B1 (en) | 2011-03-21 | 2016-07-20 | University of Reading | Transport of cells in alginate hydrogels |
JP2014514613A (en) | 2011-04-28 | 2014-06-19 | ネクシスビジョン, インコーポレイテッド | Ocular covering and refractive correction methods and devices with improved tear flow, comfort and / or applicability |
WO2014210186A2 (en) | 2013-06-26 | 2014-12-31 | Nexisvision, Inc. | Contact lenses for refractive correction |
US8678584B2 (en) | 2012-04-20 | 2014-03-25 | Nexisvision, Inc. | Contact lenses for refractive correction |
US9465233B2 (en) | 2012-04-20 | 2016-10-11 | Nexisvision, Inc. | Bimodular contact lenses |
EP2841985A1 (en) | 2012-04-20 | 2015-03-04 | Nexisvision, Inc. | Contact lenses for refractive correction |
US9395468B2 (en) | 2012-08-27 | 2016-07-19 | Ocular Dynamics, Llc | Contact lens with a hydrophilic layer |
CN102886067A (en) * | 2012-10-23 | 2013-01-23 | 深圳华明生物科技有限公司 | Artificial cornea porous support material and preparation method thereof |
WO2014176304A1 (en) * | 2013-04-25 | 2014-10-30 | The University Of Akron | One-pot synthesis of highly mechanical and recoverable double-network hydrogels |
US9341864B2 (en) | 2013-11-15 | 2016-05-17 | Nexisvision, Inc. | Contact lenses having a reinforcing scaffold |
AU2014348502B2 (en) | 2013-11-15 | 2019-08-15 | Tangible Science, Inc. | Contact lens with a hydrophilic layer |
CN103848937B (en) * | 2014-01-09 | 2016-01-20 | 湖北工业大学 | A kind of can the preparation method of the tired high strength double-layer network hydrogel repaired |
WO2015116559A1 (en) | 2014-01-29 | 2015-08-06 | Nexisvision, Inc. | Multifocal bimodulus contact lenses |
WO2016049345A1 (en) * | 2014-09-24 | 2016-03-31 | The Regents Of The University Of California | Three-dimensional bioprinted artificial cornea |
WO2016094533A1 (en) | 2014-12-09 | 2016-06-16 | Ocular Dynamics, Llc | Medical device coating with a biocompatible layer |
WO2016132182A1 (en) * | 2015-02-20 | 2016-08-25 | Cells For Cells | Devices for studying chemotaxis/adherence in cells wherein gradients and channels are formed using hydrogels |
WO2016165788A1 (en) | 2015-04-14 | 2016-10-20 | Uab Ferentis | Collagen mimetic peptide |
CN105085791B (en) * | 2015-09-13 | 2017-02-22 | 长春工业大学 | Preparation method of hydrophobic microsphere toughened and reinforced physical crosslinking double-network hydrogel |
US20170103184A1 (en) * | 2015-10-12 | 2017-04-13 | Phi Nguyen | Injectable filler |
CN109971101B (en) * | 2019-03-15 | 2021-04-23 | 广东海洋大学 | Double-network hydrogel and preparation method and application thereof |
US20220249281A1 (en) * | 2019-07-26 | 2022-08-11 | Tohoku University | Continual drug release device that can be replenished with drugs |
US20230263943A1 (en) * | 2020-04-29 | 2023-08-24 | The Board Of Trustees Of The Leland Stanford Junior University | Hydrogels for in situ-forming tissue constructs |
CN112316219B (en) * | 2020-09-29 | 2022-05-10 | 浙江大学 | Anti-adhesion hydrogel-silk scaffold composite membrane and preparation and application thereof |
CN113926001B (en) * | 2021-09-13 | 2023-03-07 | 熹微(苏州)生物医药科技有限公司 | Bionic cornea and preparation method thereof |
CN114796620B (en) * | 2022-04-24 | 2023-09-29 | 广东顺德工业设计研究院(广东顺德创新设计研究院) | Interpenetrating network hydrogel used as medical implant material and preparation method and application thereof |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5476515A (en) * | 1991-08-06 | 1995-12-19 | Autogenesis Technologies, Inc. | Method of making intraocular lenses with injectable collagen-based compositions |
US6210438B1 (en) * | 1998-04-15 | 2001-04-03 | Alcon Laboratories, Inc. | Bicomposite intraocular lens and method for its preparation |
US20020007217A1 (en) * | 2000-03-31 | 2002-01-17 | Jacob Jean T. | Surface modifications for enhanced epithelialization |
US20020007113A1 (en) * | 1999-08-26 | 2002-01-17 | March Wayne Front | Ocular analyte sensor |
US20020068013A1 (en) * | 1998-10-02 | 2002-06-06 | Mark Wilcox | Biomedical devices with antimicrobial coatings |
US20030022216A1 (en) * | 2001-06-26 | 2003-01-30 | Accelr8 Technology Corporation | Functional surface coating |
US20030100666A1 (en) * | 2001-07-16 | 2003-05-29 | Degroot Jacqueline Hermina | Compositions capable of forming hydrogels in the eye |
US6846875B2 (en) * | 2000-04-10 | 2005-01-25 | Pharmacia Groningen Bv | Hydrogels and methods for their production |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4391797A (en) * | 1977-01-05 | 1983-07-05 | The Children's Hospital Medical Center | Systems for the controlled release of macromolecules |
US4452925A (en) * | 1981-02-09 | 1984-06-05 | National Patent Development Corporation | Biologically stabilized compositions comprising collagen as the minor component with ethylenically unsaturated compounds used as contact lenses |
US4973493A (en) * | 1982-09-29 | 1990-11-27 | Bio-Metric Systems, Inc. | Method of improving the biocompatibility of solid surfaces |
US4500676A (en) * | 1983-12-15 | 1985-02-19 | Biomatrix, Inc. | Hyaluronate modified polymeric articles |
US4487865A (en) * | 1983-12-15 | 1984-12-11 | Biomatrix, Inc. | Polymeric articles modified with hyaluronate |
US4536554A (en) * | 1984-02-22 | 1985-08-20 | Barnes-Hind, Inc. | Hydrophilic polymers and contact lenses made therefrom |
US5030230A (en) * | 1986-05-16 | 1991-07-09 | Great Plains Eye Clinic, Ltd. | Corneal implant |
US4693715A (en) * | 1986-06-19 | 1987-09-15 | Abel Robert Jr | Artificial cornea |
US5112350A (en) * | 1986-10-16 | 1992-05-12 | Cbs Lens, A California General Partnership | Method for locating on a cornea an artificial lens fabricated from a collagen-hydrogel for promoting epithelial cell growth and regeneration of the stroma |
US5114627A (en) * | 1986-10-16 | 1992-05-19 | Cbs Lens | Method for producing a collagen hydrogel |
US5282851A (en) * | 1987-07-07 | 1994-02-01 | Jacob Labarre Jean | Intraocular prostheses |
US5171318A (en) * | 1987-11-09 | 1992-12-15 | Chiron Ophthalmics, Inc. | Treated corneal prosthetic device |
US5067961A (en) * | 1988-02-18 | 1991-11-26 | Autogenesis Technologies, Inc. | Non-biodegradable two phase corneal implant and method for preparing same |
US5660692A (en) * | 1988-02-24 | 1997-08-26 | Cedars-Sinai Medical Center | Method of crosslinking amino acid-containing polymers using photoactivatable chemical crosslinkers |
US5087392A (en) * | 1988-05-31 | 1992-02-11 | Sola Usa, Inc. | Method of mold contact lenses |
FR2646930B1 (en) * | 1989-05-12 | 1993-04-09 | Essilor Int | PROCESS FOR PRODUCING A DIFFRACTIVE ELEMENT, USABLE IN PARTICULAR IN THE MANUFACTURE OF ARTIFICIAL OPTICAL LENSES, AND LENSES THUS OBTAINED |
US4978352A (en) * | 1989-06-07 | 1990-12-18 | Fedorov Svjatoslav N | Process for producing collagen-based cross-linked biopolymer, an implant from said biopolymer, method for producing said implant, and method for hermetization of corneal or scleral wounds involved in eye injuries, using said implant |
CA2101773A1 (en) * | 1991-01-31 | 1992-08-01 | Toyoichi Tanaka | Interpenetrating-polymer network phase-transition gels |
IT1260154B (en) * | 1992-07-03 | 1996-03-28 | Lanfranco Callegaro | HYALURONIC ACID AND ITS DERIVATIVES IN INTERPENETRATING POLYMERS (IPN) |
AU650156B2 (en) * | 1992-08-05 | 1994-06-09 | Lions Eye Institute Limited | Keratoprosthesis and method of producing the same |
US5374515A (en) * | 1992-11-13 | 1994-12-20 | Organogenesis, Inc. | In vitro cornea equivalent model |
US5836313A (en) * | 1993-02-08 | 1998-11-17 | Massachusetts Institute Of Technology | Methods for making composite hydrogels for corneal prostheses |
AT400008B (en) * | 1993-09-29 | 1995-09-25 | Frings & Co Heinrich | DEVICE FOR ENTERING GAS IN A LIQUID |
US5656210A (en) * | 1995-03-31 | 1997-08-12 | Johnson & Johnson Vision Products, Inc. | Reaction injection molding as a process to prepare contact lenses |
US5976648A (en) * | 1995-12-14 | 1999-11-02 | Kimberly-Clark Worldwide, Inc. | Synthesis and use of heterogeneous polymer gels |
US6005160A (en) * | 1996-02-22 | 1999-12-21 | National Science Council | Heterobifunctional membrane in application of artificial cornea |
CN1208336A (en) * | 1996-11-13 | 1999-02-17 | 株式会社美你康 | Artificial cornea |
US6224893B1 (en) * | 1997-04-11 | 2001-05-01 | Massachusetts Institute Of Technology | Semi-interpenetrating or interpenetrating polymer networks for drug delivery and tissue engineering |
US5962005A (en) * | 1997-04-17 | 1999-10-05 | Rengo Co., Ltd | Transparent cellulose hydrogel and production process thereof |
CA2227827A1 (en) * | 1998-01-23 | 1999-07-23 | Unknown | In vitro artificial cornea and sclera |
EP1095076A4 (en) * | 1998-07-08 | 2002-11-06 | Sunsoft Corp | Interpenetrating polymer network hydrophilic hydrogels for contact lens |
US6361560B1 (en) * | 1998-12-23 | 2002-03-26 | Anamed, Inc. | Corneal implant and method of manufacture |
US6254637B1 (en) * | 2000-04-10 | 2001-07-03 | Lucid Korea Co., Ltd. | Artificial cornea and implantation thereof |
US6372815B1 (en) * | 2000-04-18 | 2002-04-16 | Ocular Sciences Inc | Ophthalmic lenses and compositions, and methods for producing same |
US6960617B2 (en) * | 2002-04-22 | 2005-11-01 | Purdue Research Foundation | Hydrogels having enhanced elasticity and mechanical strength properties |
WO2003093327A1 (en) * | 2002-05-01 | 2003-11-13 | Hokkaido Technology Licensing Office Co., Ltd. | Gel having multiple network structure and method for preparation thereof |
CN1662192A (en) * | 2002-06-18 | 2005-08-31 | 利兰·斯坦福初级大学董事会 | Artificial cornea |
US8025696B2 (en) * | 2004-06-18 | 2011-09-27 | National University Corporation Hokkaido University | Artificial meniscus and process of making thereof |
US20070005140A1 (en) * | 2005-06-29 | 2007-01-04 | Kim Daniel H | Fabrication and use of biocompatible materials for treating and repairing herniated spinal discs |
CN101305052B (en) * | 2005-09-09 | 2012-10-10 | 渥太华健康研究所 | Interpenetrating networks, and related methods and compositions |
-
2005
- 2005-10-04 US US11/243,952 patent/US7857849B2/en not_active Expired - Fee Related
- 2005-10-05 WO PCT/US2005/036648 patent/WO2006042272A2/en active Application Filing
- 2005-10-05 EP EP05807352A patent/EP1809207A4/en not_active Withdrawn
-
2007
- 2007-03-16 US US11/725,190 patent/US20070233240A1/en not_active Abandoned
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5476515A (en) * | 1991-08-06 | 1995-12-19 | Autogenesis Technologies, Inc. | Method of making intraocular lenses with injectable collagen-based compositions |
US6210438B1 (en) * | 1998-04-15 | 2001-04-03 | Alcon Laboratories, Inc. | Bicomposite intraocular lens and method for its preparation |
US20020068013A1 (en) * | 1998-10-02 | 2002-06-06 | Mark Wilcox | Biomedical devices with antimicrobial coatings |
US20020007113A1 (en) * | 1999-08-26 | 2002-01-17 | March Wayne Front | Ocular analyte sensor |
US20020007217A1 (en) * | 2000-03-31 | 2002-01-17 | Jacob Jean T. | Surface modifications for enhanced epithelialization |
US6846875B2 (en) * | 2000-04-10 | 2005-01-25 | Pharmacia Groningen Bv | Hydrogels and methods for their production |
US20030022216A1 (en) * | 2001-06-26 | 2003-01-30 | Accelr8 Technology Corporation | Functional surface coating |
US20030100666A1 (en) * | 2001-07-16 | 2003-05-29 | Degroot Jacqueline Hermina | Compositions capable of forming hydrogels in the eye |
Cited By (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8679190B2 (en) | 2004-10-05 | 2014-03-25 | The Board Of Trustees Of The Leland Stanford Junior University | Hydrogel arthroplasty device |
US9387082B2 (en) | 2004-10-05 | 2016-07-12 | The Board Of Trustees Of The Leland Stanford Junior University | Hydrogel arthroplasty device |
US20110166247A1 (en) * | 2006-12-07 | 2011-07-07 | David Myung | Interpenetrating polymer network hydrogel contact lenses |
US9775906B2 (en) | 2007-07-09 | 2017-10-03 | Incept Llc | Hydrogel polymeric compositions and methods |
US9125807B2 (en) | 2007-07-09 | 2015-09-08 | Incept Llc | Adhesive hydrogels for ophthalmic drug delivery |
US11324828B2 (en) | 2007-07-09 | 2022-05-10 | Incept, Llc | Hydrogel polymeric compositions and methods |
US10251954B2 (en) | 2007-07-09 | 2019-04-09 | Incept, Llc | Hydrogel polymeric compositions and methods |
US20090017097A1 (en) * | 2007-07-09 | 2009-01-15 | Sawhney Amarpreet S | Hydrogel polymeric compositions and methods |
WO2009008946A1 (en) * | 2007-07-09 | 2009-01-15 | Incept, Llc. | Hydrogel polymeric compositions and methods |
US9370485B2 (en) | 2007-07-09 | 2016-06-21 | Incept, Llc | Hydrogel polymeric compositions and methods |
US10457803B2 (en) | 2008-07-07 | 2019-10-29 | Hyalex Orthopaedics, Inc. | Orthopedic implants having gradient polymer alloys |
US8883915B2 (en) | 2008-07-07 | 2014-11-11 | Biomimedica, Inc. | Hydrophobic and hydrophilic interpenetrating polymer networks derived from hydrophobic polymers and methods of preparing the same |
US10752768B2 (en) | 2008-07-07 | 2020-08-25 | Hyalex Orthopaedics, Inc. | Orthopedic implants having gradient polymer alloys |
US20120071580A1 (en) * | 2008-07-31 | 2012-03-22 | The Board Of Trustees Of The University Of Illinois | Suturable Hybrid Superporous Hydrogel Keratoprosthesis for Cornea |
US8497023B2 (en) | 2008-08-05 | 2013-07-30 | Biomimedica, Inc. | Polyurethane-grafted hydrogels |
US8853294B2 (en) | 2008-08-05 | 2014-10-07 | Biomimedica, Inc. | Polyurethane-grafted hydrogels |
US8563027B2 (en) | 2009-02-12 | 2013-10-22 | Incept, Llc | Drug delivery through hydrogel plugs |
US8409606B2 (en) | 2009-02-12 | 2013-04-02 | Incept, Llc | Drug delivery through hydrogel plugs |
US8961501B2 (en) | 2010-09-17 | 2015-02-24 | Incept, Llc | Method for applying flowable hydrogels to a cornea |
US10226417B2 (en) | 2011-09-16 | 2019-03-12 | Peter Jarrett | Drug delivery systems and applications |
US11015016B2 (en) | 2011-10-03 | 2021-05-25 | Hyalex Orthopaedics, Inc. | Polymeric adhesive for anchoring compliant materials to another surface |
US11760830B2 (en) | 2011-10-03 | 2023-09-19 | Hyalex Orthopaedics, Inc. | Polymeric adhesive for anchoring compliant materials to another surface |
WO2013063390A1 (en) * | 2011-10-28 | 2013-05-02 | The Board Of Trustees Of The University Of Illinois | A suturable hybrid superporous hydrogel keratoprosthesis for cornea |
CN104144716A (en) * | 2011-10-28 | 2014-11-12 | 伊利诺伊大学理事会 | A suturable hybrid superporous hydrogel keratoprosthesis for cornea |
US9114024B2 (en) | 2011-11-21 | 2015-08-25 | Biomimedica, Inc. | Systems, devices, and methods for anchoring orthopaedic implants to bone |
WO2013106618A1 (en) * | 2012-01-11 | 2013-07-18 | Advanced Vision Science, Inc. | Polarized component ocular devices |
US20130231740A1 (en) * | 2012-03-05 | 2013-09-05 | Key Medical Technologies, Inc. | Polymers and methods for ophthalmic applications |
US9820850B2 (en) * | 2012-03-05 | 2017-11-21 | Key Medical Technologies, Inc. | Polymers and methods for ophthalmic applications |
US10039859B2 (en) | 2013-09-09 | 2018-08-07 | Uab Ferentis | Transparent hydrogel and method of making the same from functionalized natural polymers |
US10166314B2 (en) | 2013-10-14 | 2019-01-01 | Uab Ferentis | Regenerative prostheses as alternatives to donor corneas for transplantation |
US10736778B2 (en) | 2014-12-31 | 2020-08-11 | Microoptx Inc. | Glaucoma treatment devices and methods |
US11369591B2 (en) | 2015-05-12 | 2022-06-28 | Incept, Llc | Drug delivery from hydrogels |
US11077228B2 (en) | 2015-08-10 | 2021-08-03 | Hyalex Orthopaedics, Inc. | Interpenetrating polymer networks |
CN108778398A (en) * | 2015-09-30 | 2018-11-09 | 迈克罗欧普提克斯股份有限公司 | Dry eye treatment device and method |
US10980667B2 (en) * | 2015-09-30 | 2021-04-20 | Microoptx Inc. | Eye treatment devices and methods |
US20180280195A1 (en) * | 2015-09-30 | 2018-10-04 | Microoptx Inc. | Dry eye treatment devices and methods |
US20210220172A1 (en) * | 2015-09-30 | 2021-07-22 | Microoptx Inc. | Dry eye treatment devices and methods |
WO2017059272A1 (en) * | 2015-09-30 | 2017-04-06 | Microoptx Inc. | Dry eye treatment devices and methods |
CN108778398B (en) * | 2015-09-30 | 2021-12-14 | 迈克罗欧普提克斯股份有限公司 | Dry eye treatment device and method |
US11110200B2 (en) | 2018-07-17 | 2021-09-07 | Hyalex Orthopaedics, Inc. | Ionic polymer compositions |
US11364322B2 (en) | 2018-07-17 | 2022-06-21 | Hyalex Orthopaedics, Inc. | Ionic polymer compositions |
US10869950B2 (en) | 2018-07-17 | 2020-12-22 | Hyalex Orthopaedics, Inc. | Ionic polymer compositions |
US10792392B2 (en) | 2018-07-17 | 2020-10-06 | Hyalex Orthopedics, Inc. | Ionic polymer compositions |
Also Published As
Publication number | Publication date |
---|---|
EP1809207A2 (en) | 2007-07-25 |
US7857849B2 (en) | 2010-12-28 |
EP1809207A4 (en) | 2010-04-28 |
US20060083773A1 (en) | 2006-04-20 |
WO2006042272A3 (en) | 2007-02-08 |
WO2006042272A2 (en) | 2006-04-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20070233240A1 (en) | Intraocular lens implant | |
Peppas et al. | Hydrogels | |
US7857447B2 (en) | Interpenetrating polymer network hydrogel contact lenses | |
US7909867B2 (en) | Interpenetrating polymer network hydrogel corneal prosthesis | |
US6747090B2 (en) | Compositions capable of forming hydrogels in the eye | |
US6673886B2 (en) | High refractive index hydrogel compositions for ophthalmic implants | |
RU2571091C2 (en) | Acrylic materials with hugh refractive index with reduced quantity of blinding flashes for ophthalmological devices | |
US8821583B2 (en) | Interpenetrating polymer network hydrogel | |
US9820850B2 (en) | Polymers and methods for ophthalmic applications | |
JP2006516038A (en) | Biosynthetic substrates and uses thereof | |
TW201410719A (en) | Polymers and nanogel materials and methods for making and using the same | |
US20040054026A1 (en) | Elastomeric, expandable hydrogel compositions | |
JP2707497B2 (en) | Ophthalmic implant and manufacturing method thereof | |
US7847046B2 (en) | Ophthalmic and otorhinolaryngological device materials containing phenylene-siloxane macromers | |
US20100303911A1 (en) | Hydrogel systems | |
WO1997024382A1 (en) | Foldable intraocular lens materials | |
JP2005531363A (en) | Surface modified intraocular lens | |
US8192485B2 (en) | Reversible hydrogel systems and methods therefor | |
US20110184513A1 (en) | Artificial corneal implant | |
US20110182968A1 (en) | Interpenetrating polymer network hydrogel corneal prosthesis | |
JP2004535511A (en) | Composition capable of forming hydrogels in the eye | |
JP2023052498A (en) | Polymers and methods for ophthalmic applications | |
JP5009809B2 (en) | Amphiphilic block copolymers and uses thereof | |
JP2010512225A (en) | Regular polymer systems and intraocular lenses | |
US20100280147A1 (en) | High refractive index interpenetrating networks for ophthalmic applications |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FRANK, CURTIS W.;TA, CHRISTOPHER;MYUNG, DAVID;AND OTHERS;REEL/FRAME:019434/0098 Effective date: 20070531 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |